
-
Corcept Therapeutics NasdaqCM:CORT Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Location: 101 Redwood Shores Parkway, Redwood City, CA, 94065, United States | Website: https://www.corcept.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
7.917B
Cash
322.8M
Avg Qtr Burn
N/A
Short % of Float
14.24%
Insider Ownership
11.48%
Institutional Own.
79.82%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Korlym® (Relacorilant) Details Hypercortisolism, Cushing’s syndrome | Phase 4 Data readout | |
Korlym® (Relacorilant) Details Hypercortisolism | PDUFA Approval decision | |
Relacorilant + Nab-paclitaxel Details Platinum-Resistant Ovarian Cancer | NDA Submission | |
Korlym® (Relacorilant) Details Hypercortisolism, Cushing’s syndrome | NDA Submission | |
Miricorilant Details Non-alcoholic steatohepatitis | Phase 2b Data readout | |
Relacorilant (GR antagonist) + Enzalutamide Details Cancer, Castration-resistant prostate cancer, Solid tumor/s, Prostate cancer | Phase 2 Data readout | |
Relacorilant + Nab-Paclitaxel & Bevacizumab Details Platinum-Resistant Ovarian Cancer | Phase 2 Data readout | |
Phase 2 Data readout | ||
Miricorilant Details Obesity, Antipsychotic-Induced Weight Gain | Phase 2 Update | |
Relacorilant + pembrolizumab Details Cancer, Adrenal cancer | Phase 1b Update | |
Relacorilant + Nab-paclitaxel Details Pancreatic cancer | Failed Discontinued |